Will tumors disappear when taking imatinib?

Imatinib (Imatinib) is a targeted drug mainly used to treat tumor diseases such as chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST). Its mechanism of action is to prevent the growth and division of tumor cells by inhibiting BCR-ABL tyrosine kinase (an abnormal protein produced by genetic mutations).

For chronic myeloid leukemia, imatinib can effectively control the disease and significantly reduce the number of leukemia cells. Some patients can achieve complete remission, that is, abnormal leukemia cells are no longer detected in the blood and bone marrow. However, complete remission does not mean the complete disappearance of tumors or leukemia cells, but the continued use of imatinib to control the disease and prevent recurrence.

In the treatment of gastrointestinal stromal tumors, imatinib can shrink tumors and effectively delay disease progression in some patients. For some patients with surgically resectable disease, long-term use of imatinib after surgery can also help reduce the risk of recurrence. However, whether the tumor completely disappears depends on several factors, including the size and location of the tumor, the timing of treatment, and the patient's response to the drugs.

Although imatinib can significantly improve patient prognosis, it does not guarantee complete tumor disappearance in all patients. Some patients may develop drug resistance after long-term use of drugs, causing tumor cells to re-grow. Therefore, it is very important to regularly monitor the effects of treatment and adjust the treatment plan in a timely manner.

In general, imatinib is a very effective targeted drug that can help control and shrink tumors, but whether the tumors completely disappear depends on the individual's condition and treatment response. Ongoing treatment and medical observation are key to ensuring long-term efficacy.